The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | 48-month survival analysis of BENEFIT: Isa-VRd for transplant-ineligible newly diagnosed myeloma
In this video, Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the 48-month analysis of the BENEFIT study (NCT04751877), a trial which compared isatuximab plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd) to Isa-Rd in transplant-ineligible newly diagnosed multiple myeloma. Prof. Leleu highlights that the early positive impact of the Isa-VRd regimen on measurable residual disease (MRD) translated into long-term survival benefit. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in one of the specificities, particularity of the BENEFIT study, is that we only have an impact in the two arms initially as induction. And the early time point MRD analysis demonstrated a very clear, quite important difference across arms. But the question then is, will that translate into survival if the impact is only during the induction? So what we are showing is that the control arm is very good...
So in one of the specificities, particularity of the BENEFIT study, is that we only have an impact in the two arms initially as induction. And the early time point MRD analysis demonstrated a very clear, quite important difference across arms. But the question then is, will that translate into survival if the impact is only during the induction? So what we are showing is that the control arm is very good. The experimental arm is better. And it takes time to demonstrate the survival difference that sort of MRD alluded to initially. But when you project that 10 years, you clearly see that approximately 40% of the patients will have not relapsed, not died in the Control, while around 60% of the patients would have not relapsed, not died in the experimental arm. And the difference is quite striking and significant.
So this means, number one, if you have an early MRD impact, you’ll have a survival translation. Number two, the more impact you have, the more survival difference in hand you have. Number three, if your control arm is very good, you have to be very patient because you’ll see that difference, but it might take 10 years. Number four, quadruplet regimen like IsaVRd, isatuximab plus bortezomib, lenalidomide, and dexamethasone, is currently projected around eight to nine years. But our data and benefits say that it could actually be beyond 10 years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
